BOLT BIOTHERAPEUTICS INC (BOLT) Stock Overview
USA - NASDAQ:BOLT - US0977022039 - Common Stock
BOLT Key Statistics, Chart & Performance
The current stock price of BOLT is 5.7508 USD. In the past month the price increased by 9.96%. In the past year, price decreased by -54.1%.
BOLT Latest News, Press Relases and Analysis
BOLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.01 | 51.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B |
Related stock screener links
About BOLT
Company Profile
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 52 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Company Info
BOLT BIOTHERAPEUTICS INC
900 Chesapeake Drive
Redwood City CALIFORNIA 94063 US
CEO: Randall C. Schatzman
Employees: 52
Phone: 16506659295
BOLT BIOTHERAPEUTICS INC / BOLT FAQ
What is the stock price of BOLT BIOTHERAPEUTICS INC today?
The current stock price of BOLT is 5.7508 USD. The price decreased by -1.91% in the last trading session.
What is the ticker symbol for BOLT BIOTHERAPEUTICS INC stock?
The exchange symbol of BOLT BIOTHERAPEUTICS INC is BOLT and it is listed on the Nasdaq exchange.
On which exchange is BOLT stock listed?
BOLT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BOLT BIOTHERAPEUTICS INC stock?
11 analysts have analysed BOLT and the average price target is 34.34 USD. This implies a price increase of 497.13% is expected in the next year compared to the current price of 5.7508. Check the BOLT BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BOLT BIOTHERAPEUTICS INC worth?
BOLT BIOTHERAPEUTICS INC (BOLT) has a market capitalization of 11.04M USD. This makes BOLT a Nano Cap stock.
How many employees does BOLT BIOTHERAPEUTICS INC have?
BOLT BIOTHERAPEUTICS INC (BOLT) currently has 52 employees.
What are the support and resistance levels for BOLT BIOTHERAPEUTICS INC (BOLT) stock?
BOLT BIOTHERAPEUTICS INC (BOLT) has a support level at 5.12 and a resistance level at 5.8. Check the full technical report for a detailed analysis of BOLT support and resistance levels.
Is BOLT BIOTHERAPEUTICS INC (BOLT) expected to grow?
The Revenue of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to decline by -46.17% in the next year. Check the estimates tab for more information on the BOLT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BOLT BIOTHERAPEUTICS INC (BOLT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BOLT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BOLT, evaluating the profitability, health, valuation and growth aspects
- BOLT BIOTHERAPEUTICS INC (BOLT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BOLT BIOTHERAPEUTICS INC (BOLT) Sales and EPS estimates to see what analysts future expectations are.
- BOLT BIOTHERAPEUTICS INC (BOLT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BOLT BIOTHERAPEUTICS INC (BOLT) Insider and Institutional Ownership to learn about the owners and their transactions.
- BOLT BIOTHERAPEUTICS INC (BOLT) Stock Chart to make your own analysis
- BOLT BIOTHERAPEUTICS INC (BOLT) Latest news and press-releases to stay up to date.
Does BOLT BIOTHERAPEUTICS INC (BOLT) stock pay dividends?
BOLT does not pay a dividend.
When does BOLT BIOTHERAPEUTICS INC (BOLT) report earnings?
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of BOLT BIOTHERAPEUTICS INC (BOLT)?
BOLT BIOTHERAPEUTICS INC (BOLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-25.86).
What is the Short Interest ratio of BOLT BIOTHERAPEUTICS INC (BOLT) stock?
The outstanding short interest for BOLT BIOTHERAPEUTICS INC (BOLT) is 4.12% of its float. Check the ownership tab for more information on the BOLT short interest.
BOLT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BOLT. When comparing the yearly performance of all stocks, BOLT is a bad performer in the overall market: 90.12% of all stocks are doing better.
BOLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLT. BOLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BOLT Financial Highlights
Over the last trailing twelve months BOLT reported a non-GAAP Earnings per Share(EPS) of -25.86. The EPS increased by 21.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.17% | ||
| ROE | -130.56% | ||
| Debt/Equity | 0 |
BOLT Forecast & Estimates
11 analysts have analysed BOLT and the average price target is 34.34 USD. This implies a price increase of 497.13% is expected in the next year compared to the current price of 5.7508.
For the next year, analysts expect an EPS growth of 19.97% and a revenue growth -46.17% for BOLT